A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Conditions
Meningioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama, Birmingham, Alabama, United States
Mayo Clinic_Arizona, Phoenix, Arizona, United States
Mayo Clinic_Jacksonville, Jacksonville, Florida, United States
Baptist Health Miami Cancer Institute, Miami, Florida, United States
Washington University School of Medicine, Bay Saint Louis, Mississippi, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Mayo Clinic_Rochester, Rochester, New York, United States
Duke University, Durham, North Carolina, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
UT Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
Inova Center for Personalized Health, Fairfax, Virginia, United States
UW Carbone Cancer Center, Madison, Wisconsin, United States
Study leads
Study Director
Exelixis